問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳婉真

Recruiting

List

3Cases

2018-11-01 - 2021-01-31

Phase II

A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Relationships of Different Doses of JNJ-53718678 in Children >=28 Days and <=3 Years of Age With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus Infection

  • Condition/Disease

    Respiratory Syncytial Virus(RSV) Infection

  • Test Drug

    JNJ-53718678/Placebo

Participate Sites
6Sites

Recruiting6Sites

2019-01-01 - 2020-12-31

Others

A Phase III Study of Immunogenicity and Safety Evaluation of AdimFlu-S (QIS) Quadrivalent Inactivated Influenza Vaccine in Healthy Subjects Aged 6 Months Old to 35 Months Old

  • Condition/Disease

    Influenza

  • Test Drug

    AdimFlu-S Quadrivalent Inactivated Influenza Vaccine(AdimFlu-S(QIS))

Participate Sites
9Sites

Recruiting8Sites

2019-09-20 - 2022-12-31

Phase II

A Phase 2A, 2-Part Open-Label, Non-Randomized, Multicenter, Single and Multiple Dose Trial to Evaluate Pharmacokinetics, Safety and Tolerability of Ceftazidime and Avibactam in Neonates and Infants From Birth to Less Than 3 Months of Age With Suspected or Confirmed Infections Due to Gram-Negative Pathogens Requiring Intravenous Antibiotic Treatment

  • Condition/Disease

    Gram-negative Bacterial Infection

  • Test Drug

    ceftazidime-avibactam

Participate Sites
7Sites

Recruiting7Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB